Harnessing the Power of CannabinoidsTM

Led by a world class team, BayMedica is developing efficient and scalable biosynthetic and synthetic chemistry processes to deliver a portfolio of natural cannabinoids including CBC, CBDV and THCV as well as novel cannabinoid analogs for life science, pharmaceutical, nutraceutical, cosmetic and animal health applications.

The BayMedica Platform

Biosynthesis is a multi-step process where living organisms use enzymes to catalyze the conversion of simple substrates into complex products. Cannabinoids are one class of compounds synthesized by Cannabis, however, the Cannabis sativa plant is an inefficient biological factory for even the most prevalent compounds such as THC and CBD, which comprise only 2-5% of the biomass of the plant. Cannabis is even less efficient at synthesizing the 100+ minor cannabinoids such as CBC, CBN and CBDV that typically comprise less than 0.1% of plant biomass.

The BayMedica platform solves this issue by engineering common yeast to convert sugar into cannabinoids, including common and rare natural varieties, as well as novel cannabinoid analogs of pharmaceutical interest. Our platform produces rare, non-intoxicating, naturally-occurring cannabinoids and novel cannabinoid analogs. We also leverage our experience in synthetic chemistry where applicable. BayMedica cannabinoids have a wide variety of applications in the pharmaceutical, cosmetic, consumer and animal health industries.

.

Bioreactor

BayMedica Products

.

Prodiol®

Our Prodiol family of natural pharmaceutical-grade, cannabinoids are available as individual ingredients for inclusion into consumer health and wellness products.

Our Team

Shane Johnson, MD

Shane Johnson, MD

Co-Founder, President & CEO

Dr. Johnson is co-founder of a Nevada cannabis cultivator and manufacturer, with extensive experience in strategy and startup management. He holds a BS in neuroscience from Brown University and an MD from Stanford University.

Meet Shane

Philip Barr, PhD

Philip Barr, PhD

Co-Founder, Chief Scientific Officer

Dr. Barr is an expert in polyketide biosynthesis in yeast (cannabinoids are members of the polyketide family) with over 50 patents, 200 manuscripts, and multiple commercial products. He holds a PhD in organic chemistry with over 30 years industry experience.

Meet Phil

Charles Marlowe, PhD

Charles Marlowe, PhD

Co-Founder, Director of Chemistry

Dr. Marlowe has 25 patents issued and over 30 publications. He has been instrumental in developing small molecule therapeutics. He holds a PhD in organic chemistry from UC Berkeley.

Meet Charles

Dave Kent

Dave Kent

VP Corporate Development

Mr. Kent has extensive experience in corporate finance with Smith Barney, Lehman Brothers, Fortinbras Asset Management & Wells Fargo. He has served as Founder and CFO of Arriva Pharmaceuticals, CEO at DOR Biopharma & CEO Karuna Biomedical.

Meet Dave

Jim Kealey, PhD

Jim Kealey, PhD

VP Research & Development

Dr. Kealey has extensive experience in synthetic biology and polyketide synthesis. He has managed large teams and holds a PhD in pharmaceutical chemistry from UCSF.

Meet Jim

Chris Meiering, PhD

Chris Meiering, PhD

VP - Commercialization

Dr. Meiering holds a PhD in microbiology from the University of Washington and has over 20 years experience in the companion animal industry.

Meet Chris

Jianping Sun, PhD

Jianping Sun, PhD

Director of Molecular Biology

Dr. Sun earned a PhD in biochemistry and molecular biology from USTC – China. She is experienced in fermentation, metabolic engineering and systems biology.

Meet Jianping

Discover the Future of Cannabinoids